NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. It works only in coordination with the primary cookie. RADNOR, Pa., Nov. 9, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ), ("NRx Pharmaceuticals" or the "Company"), a . --Company to Host Conference Call November 14, 2022, at 8:00AM ET---. Conference Call and Webcast Details. RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ --NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022. This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Careers The NRx team reaches beyond boundaries, thinks beyond standards and explores beyond borders. LeBron hurt late in Clippers' 114-101 win over Lakers 6 hours ago Investor Relations Rooms Rankings Earnings Newsletters. About the company Risk Analysis Has less than 1 year of cash runway Shares are highly illiquid Makes less than USD$1m in revenue ($0) RADNOR, Pa., Nov. 9, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3 . NRx Pharmaceuticals (www.nrxpharma.com) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients . The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". About NRx Pharmaceuticals NRx Pharmaceuticals ( www.nrxpharma.com ) (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients. (PRNewsfoto/NRx Pharmaceuticals) H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. I look forward to leading the Company, working with Robert and the NRx Pharmaceuticals leadership in its quest to bring NRX-101, a potentially life-saving medicine, to patients.. What happened. This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Companys management. The gross proceeds from the private placement are expected to be. Dismiss. NRx Pharmaceuticals, Inc. (Nasdaq: ) ('NRx Pharmaceuticals', the 'Company'), a clinical-stage, biopharmaceutical company today announced that management . HubHead Corp. is focused on helping the worlds leading asset-intensive businesses achieve excellence in operations and maintenance by getting their EAM/CMMS data right, and keeping it right. We are leaders in discovering and developing a new class of drugs that modulate protein levels by . CORPORATE CONTACT The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. This news confirms the company's ability to complete Phase 3 trials among other corporate projects. En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. These cookies ensure basic functionalities and security features of the website, anonymously. The cookies is used to store the user consent for the cookies in the category "Necessary". The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation and behavior (ASIB) remains electroconvulsive therapy (ECT). Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Companys strategies, plans, objectives, and goals. Tim McCarthy This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-closes-11-million-unsecured-debt-financing-301669870.html. HubHead Corp. is headquartered in Toronto, Ontario, Canada, and has representation around the globe. About NRx Pharmaceuticals NRx Pharmaceuticals (Nasdaq:NRXP) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients. NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. He has also held roles at Eli Lily and Wyeth, and earlier in his career he worked for Deutsche Bank and for various consulting firms. Expanded Access Policy on RTT: Aviptadil needs to be requested by a physician. Sign Up. Jobs People Learning Dismiss Dismiss. This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services. RADNOR, Pa., March 8, 2022 - NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately. The Company's right to satisfy the redemption amount in common stock is subject to certain conditions. Steves passion to provide breakthrough therapies to address critical unmet needs positions the Company for success, said Patrick Flynn, a member of the Companys Board of Directors. Dismiss. The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Based on the results of a Phase 2 proof-of-concept study, NRX-101 received Breakthrough Therapy Designation from the FDA for the treatment of severe bipolar depression in patients with ASIB after initial stabilization with ketamine or other effective therapy. Please certify that you are a healthcare professional by clicking the appropriate link below. Dismiss. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-third-quarter-2022-results-on-november-14-2022-301674138.html. A critical part of this role is providing high quality engaging content to support the sales cycle from start to finish and accelerate the sales cycle and pipeline growth. Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional . Powered by Madgex Job Board Software, NRx Pharmaceuticals to Host Conference Call & Webcast. IIBR PARTNERSHIP NRx said July 12 that it signed a Memorandum of Understanding with the Government of Israel to license exclusive worldwide development, manufacturing, and marketing rights to a novel Coronavirus vaccine developed by the Israel Institute for Biological Research (IIBR). The BriLife vaccine (technical name VSV G 1) is based . Not an offer or recommendation by Stocktwits. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. In order to register for job and employment assessment, proceed from this section. Cancel. NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. Additional details regarding the purchase and the terms of the Notes may be found in the Company's Current Report on Form 8-K to be filed with the Securities and Exchange Commission. NRx Pharmaceuticals Third Quarter 2022 Earnings Call. We have the courage to try what others have not yet attempted. mcogan@nrxpharma.com, INVESTOR RELATIONS Our website uses cookies to ensure best user experience. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. Rooms Rankings Earnings Newsletters. You can unsubscribe from these communications at any time. Contact Email investors@neurorxpharma.com. View our. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837. NRX-101 is now manufactured via a commercial-stage process. A load balancing cookie set to ensure requests by a client are sent to the same origin server. NASDAQ 0.00%. NRX Careers. NRx Pharmaceuticals, Inc. Nov 10, 2022, 6:47 AM ET Trending now. Private Securities Litigation Reform Act of 1995 . A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call. Dismiss. HubHead is looking a motivated and driven entry-level Inside Sales Representative to work closely with our team. These cookies will be stored in your browser only with your consent. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide. Implementing RDS-PP or KKS in Power Generation, 7030 Woodbine Ave., Suite 500, Markham, Ontario L3R 6G2, Canada. Nurix is a clinical-stage, science-focused company committed to bringing novel, first-in-class therapies to patients. S&P 500 0.00%. Founder & Chief Scientist Read Bio Michael Kunz General Counsel & Corporate Secretary Read Bio Philip T. Lavin, Ph.D. The Inside Sales Representative is responsible for identifying, calling and establishing meetings with qualified contacts within targeted segments. On July 12, 2022, NRx Pharmaceuticals, Inc. received a written notification (the Notice") from the Nasdaq Stock Market LLC (Nasdaq") indicating that the Registrant was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the Registrant's closing bid price for its common stock was below $1.00 per share for the last thirty (30 . NRx Pharmaceuticals is committed to protecting and respecting your privacy, and we'll only use your personal information to contact you if you subscribe to our newsletter. Clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The Company issued to the investors in the private placement unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 2,727,273 shares . Mr. Willard is currently serving a six-year term from 2018-2024 as a presidential appointee to the National Science Board. Investor Relations Sr. Director, Global Communications NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing Enabling the Company to Complete Phase 3 Trials. NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential. All rights reserved. NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022. 3rd Party Ad. We are pleased that Streeterville Capital has recognized the extraordinary potential of NRX-101, delivered conveniently as an oral medicine, to target the unmet medical needs of this patient population. This cookie is used for counting the new visitors to the website by assigning a unique visitor ID. About NRx Pharmaceuticals . NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq. CORPORATE CONTACT NRX Pharmaceuticals Inc 0.88 0.05 (6.61%) Watch. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price. Trending now. HubHead Corp. is headquartered in Toronto, Ontario, Canada, and has representation around the globe. suzanne.messere@sternir.com, View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-closes-11-million-unsecured-debt-financing-301669870.html, 1985 - 2022 BioSpace.com. The cookie is used to store the user consent for the cookies in the category "Other. Suzanne Messere Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Log In. ACCESSWIRE. Cautionary Note Regarding Forward-Looking Statements. "Someone attempts suicide every 27 seconds in the United States and the only approved treatment of suicidal bipolar depression remains electroshock therapy. Sr. Director, Global Communications Analytical cookies are used to understand how visitors interact with the website. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. 3rd Party Ad. NRX-101 is an investigational treatment for bipolar depression in patients with Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB) Read more. By Chris MacDonald, InvestorPlace Contributor May 26, 2022, 2:26 pm EDT Shareholders in NRx Pharmaceuticals (NASDAQ: NRXP) have seen a 60% decline today This came as the Data Safety. Our website uses cookies to improve your experience while you navigate through the website. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. Investor Relations NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call. This cookie is set by GDPR Cookie Consent plugin. All rights reserved. Up to 50% of individuals with Bipolar Disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide. NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022 or early Q1/2023. Head of Operations & Chief Commercial Officer Read Bio Molly Cogan Senior Director, Global Communications Read Bio Randy Guggenheimer Chief Business Officer Read Bio Jonathan C. Javitt, M.D., M.P.H. Necessary cookies are absolutely essential for the website to function properly. This cookie is used to identify the new visitors to the website. Stock Market News for Traders and Investors Most of our colleagues operate out of our clinical HQ in Radnor, PA, near Philadelphia. You also have the option to opt-out of these cookies. This cookie is set by GDPR Cookie Consent plugin. RADNOR, Pa., Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced. Blaze Your Trail With Us. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 . NRX-101 is a patented fixed dose combination of D-cycloserine and Lurasidone, neither of which has shown addiction potential. Mr. Willards career in financial services includes government service as Associate Director of the Federal Deposit Insurance Corporation (FDIC), where he served in the United States Senior Executive Service (SES) from 1991-1994, and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and Washington, D.C. Mr. Willard earned his undergraduate degree from Williams College and attended Yale University where he earned a JD in law. NRx Pharmaceuticals is led by executives who . #NRXPharma #NRxPharmaceuticals . This announcement of NRx Pharmaceuticals, Inc. includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Please enter a search term. The cookie is used to store the user consent for the cookies in the category "Performance". Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. MEDIA CONTACT: Jack Hirschfield Head of Corporate Communications, NRx jhirschfield@nrxpharma.com 512-674-5163 INVESTOR RELATIONS Eric Goldstein The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and . Join now Sign in NRx Pharmaceuticals, Inc.'s Post NRx Pharmaceuticals, Inc. 3,724 followers The Noteholder has the right to redeem up to $1,000,000 of the outstanding balance of the Note per month starting 6 months after the issuance date. This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains. Sign Up. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in . Sr. Director, Global Communications Real-time trade and investing ideas on NRX Pharmaceuticals Inc NRXP from the largest community of traders and investors. Watch Live ; News. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions. Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials. RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. RADNOR, Pa., March 18, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed. Log In. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Payments may be made by the Company at its option in: (i) cash, (ii) shares of our common stock, or (iii) a combination of cash and shares of our common stock. We are invested in making this a great place for new grads to work! RADNOR, Pa., Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in unsecured debt financing (the "Note") from Streeterville Capital, LLC, a Utah limited liability company. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT). Top reasons you could be turned away from the polls Top Stories. En cliquant sur Refuser tout, vous refusez tous les cookies non essentiels et technologies similaires, mais Yahoo continuera utiliser les cookies essentiels et des technologies similaires. A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. A replay will be available following the call on the Company's website. NRx is chaired by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in. Shares of NRx Pharmaceuticals ( NRXP -3.24%) were trading 70.1% higher as of 11:58 a.m. EDT on Thursday after the company announced that it had validated a formulation for COVID-19 . Powered by Madgex Job Board Software. We look forward to Steves leadership of the Company in the next stages of growth to benefit patients, our shareholders, and the broader NRx team.. YouTube sets this cookie to store the video preferences of the user using embedded YouTube video. The Sales Executive will ideally be based in Germany or the Netherlands and be responsible for developing and growing strategic relationships within asset-intensive industries on a named account basis in the region. HubHead is looking for aTechnical Services Analyst & IT Administrator to manage our solutions hosted in the Amazon Cloud (AWS) and support our customers. This funding, together with our cash on hand, will support the Phase 3 trial outlined in our Special Protocol Agreement with the U.S. Food and Drug Administration targeting patients with bipolar depression and acute suicidal ideation" said Stephen Willard, CEO of NRx Pharmaceuticals. This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website. Mr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or . Management will host the call, followed by a question-and-answer period. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality. 2020 HubHead Corp. All rights reserved. Dismiss. Phone Number +1 484.254.6134. RADNOR, Pa., July 13, 2022 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): (NRx Pharmaceuticals, or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer (CEO) and a member of the Companys Board of Directors. Find the latest NRx Pharmaceuticals, Inc. (NRXPW) stock quote, history, news and other vital information to help you with your stock trading and investing. This cookie is used to shoot certain codes on the first display of the page and also to enhance the speed of the website. The company will host a conference call and webcast on November 14, 2022, 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. Dismiss. Local News; California; National & World News; Entertainment Suzanne Messere Reporting to the President, the Director of Product Marketing is responsible for leading a small team to develop and execute clearly defined marketing and communications strategy in a hands-on manner that supports consistent business growth and brand awareness. We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals current needs. PR Newswire -6.02%. Also Known As NeuroRx. If you suffered significant losses and wish to serve as lead plaintiff of the NRx Pharma class action lawsuit, please provide your information by clicking here.You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.Lead plaintiff motions for the NRx Pharma class action lawsuit must be filed with the court no later than March . This is a session cookie set during the first display of the page on each visit. NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as PTSD and other indications. Join now Sign in NRx Pharmaceuticals, Inc.'s Post NRx Pharmaceuticals, Inc. 3,727 followers Please enter a search term. RADNOR, Pa., November 7, 2022 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in unsecured debt financing (the "Note") from Streeterville Capital, LLC, a Utah limited liability company. The Company has the option to prepay the Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. These cookies track visitors across websites and collect information to provide customized ads. CORPORATE CONTACT tim@lifesciadvisors.com. 1.2K subscribers in the StockTitan community. Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies, Proven track record of creating value for shareholders, National Science Board Presidential Appointee, 2018-2024, Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade Financial. Records the default button state of the corresponding category & the status of CCPA. NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022. The Company intends to use the net proceeds from the Note (approximately $10 million) to support its NRX-101 development programs for the treatment of suicidal bipolar depression and PTSD and for general corporate purposes. Molly Cogan I am honored to have been chosen by the NRx Pharmaceuticals Board to lead the Company as it conducts its trials for NRX-101 in the treatment of Suicidal Bipolar Depression and continues to develop its pipeline of drugs for depression, PTSD, and other potential neuroscience indications based on more than 90 issued and pending patents worldwide, said Willard. A replay will be available following the call on the Company's website.. RADNOR, Pa., November 9, 2022 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress . This cookie is used by the WPForms WordPress plugin. Open Positions: NRX Pharmaceuticals Inc (NASDAQ: NRXP) shares are trading higher by 54.1% at $10.45 after the company announced progress on the worldwide commercial-scale development of ZYESAMI. Dismiss. Dismiss. DOW 0.00%. YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages. About NRx Pharmaceuticals. NRX-101 is one of the first oral antidepressants currently in late stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, PTSD and other indications. We are a dynamic company committed to our mission of bringing hope to life. mcogan@nrxpharma.com, INVESTOR RELATIONS These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. Description: NRx Pharmaceuticals pipeline includes medicinal candidates in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Distress (ARDS) in partnership with Relief Therapeutics, AG, and the first drug in development to treat Bipolar Depression in Patients with Acute Suicidality. Top Stories The Companys interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer. Prior to Cellphire, he served as CEO of publicly traded Flamel Technologies now known as Avadel Pharmaceuticals. NRx Pharmaceuticals - BriLife. On August 18, 2021, NRx Pharmaceuticals, Inc. (the "Company") announced the upcoming departure of William Fricker, Chief Financial Officer (CFO) and Treasurer. Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . Type: Self-propagating COVID-19 live virus vaccine developed by the Israel Institute for Biological Research (IIBR) under an exclusive license from the Israel . Mr. Fricker's last day with the Company will be August 30, 2021. NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. He holds a B.A. NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference, CEO Update on Recent Findings Related to Serotonin and its Role in Depression, NRx Pharmaceuticals Announces Leadership Transition.
Utrgv Admission Requirements, Best Night Clubs In Colorado Springs, Group Marriage Definition, Key Realty School Las Vegas Login, Harvest Prayer Request, Pitt Shuttle Tracker App, Premier Gpo Hospitals, Hotel Porta Fira Email, How To Pronounce Amenable,